|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009429,
umls-concept:C0010711,
umls-concept:C0023434,
umls-concept:C0030705,
umls-concept:C0059985,
umls-concept:C0069717,
umls-concept:C0205390,
umls-concept:C0349631,
umls-concept:C0393022,
umls-concept:C0556895,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-1-9
|
|
pubmed:abstractText |
Richter's syndrome (RS) and fludarabine-refractory chronic lymphocytic leukemia (CLL) are associated with poor clinical outcomes. We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BrownJennifer RJR,
pubmed-author:EstrovZeevZ,
pubmed-author:FerrajoliAlessandraA,
pubmed-author:FiorentinoAlbertA,
pubmed-author:Garcia-ManeroGuillermoG,
pubmed-author:KantarjianHagop MHM,
pubmed-author:KeatingMichael JMJ,
pubmed-author:KippsThomas JTJ,
pubmed-author:KurzrockRazelleR,
pubmed-author:LernerSusanS,
pubmed-author:O'BrienSusanS,
pubmed-author:PlunkettWilliamW,
pubmed-author:Ravandi-KashaniFarhadF,
pubmed-author:TsimberidouApostolia MAM,
pubmed-author:WenSijinS,
pubmed-author:WierdaWilliam GWG
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
196-203
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18182662-Adult,
pubmed-meshheading:18182662-Aged,
pubmed-meshheading:18182662-Antibodies, Monoclonal,
pubmed-meshheading:18182662-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18182662-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18182662-Chi-Square Distribution,
pubmed-meshheading:18182662-Cytarabine,
pubmed-meshheading:18182662-Drug Administration Schedule,
pubmed-meshheading:18182662-Female,
pubmed-meshheading:18182662-Humans,
pubmed-meshheading:18182662-Infusions, Intravenous,
pubmed-meshheading:18182662-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:18182662-Lymphoma, Non-Hodgkin,
pubmed-meshheading:18182662-Male,
pubmed-meshheading:18182662-Middle Aged,
pubmed-meshheading:18182662-Organoplatinum Compounds,
pubmed-meshheading:18182662-Proportional Hazards Models,
pubmed-meshheading:18182662-Research Design,
pubmed-meshheading:18182662-Statistics, Nonparametric,
pubmed-meshheading:18182662-Survival Analysis,
pubmed-meshheading:18182662-Syndrome,
pubmed-meshheading:18182662-Treatment Outcome,
pubmed-meshheading:18182662-Vidarabine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
|
pubmed:affiliation |
University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA. atsimber@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
